Contents......Page 8
List of contributors......Page 13
Section I Headache-related disability......Page 20
1 Overview of headache prevalence, burden, and management......Page 22
2 Measuring headache disability......Page 34
3 Benefits of treatment on headache disability—a personal view on selected data......Page 46
4 Comparing disability and psychological factors in migraine and transformed migraine......Page 61
5 Cognitive efficiency following migraine therapy......Page 65
6 Comparative evolution of MIDAS score after monotherapy with triptans......Page 71
7 Disability-adjusted life years (DALYs) and MIDAS in Japan......Page 76
8 Disability in German headache sufferers: evaluation of a German headache disability inventory......Page 81
9 MIDAS as a tool for monitoring the benefits of treatment strategies over time......Page 86
10 The MIDAS questionnaire in children and young adolescents with headache: a pilot study......Page 91
11 Relationship between disability and quality of life in migraine......Page 94
12 Migraine in France in 2000: epidemiological data......Page 98
13 Validation of the Headache Impact Test™ using patient-reported symptoms and headache severity......Page 106
14 Headache-related disability: discussion summary......Page 112
Section II Patient-centred measures: health-related quality of life......Page 116
15 Measuring health-related quality of life: general principles......Page 118
16 Effect of headache on quality of life......Page 126
17 Assessment of the responsiveness of the Migraine-Specific Quality of Life Questionnaire (version 2.1)......Page 135
18 Comparison of the impact of eletriptan versus sumatriptan on migraine-specific quality of life......Page 140
19 Impact of cluster headache on health-related quality of life......Page 145
20 Improvement in migraine-specific quality of life with eletriptan (Relpax™) as compared to Cafergot®......Page 148
21 Improvements in health-related quality of life with long-term use of sumatriptan therapy for migraine......Page 153
22 Psychometric evaluation of a computerized program to assess migraine-specific quality of life in clinical practice......Page 159
23 Quality of life and disability in transformed migraine with drug overuse......Page 163
24 Quality of life and migraine: a multicentre Spanish study......Page 167
25 Patient-centred measures: health-related quality of life: discussion summary......Page 172
Section III Family burden, comorbidities, and health-care utilization......Page 174
26 Family impact of migraine......Page 176
27 Migraine comorbidity with stroke, epilepsy, and major depression......Page 183
28 Health-care utilization for headache......Page 192
29 Functional improvement in migraine patients treated with oral eletriptan versus sumatriptan: a pooled analysis......Page 198
30 Health-care utilization for in-patient headache therapy......Page 204
31 Self-described ‘sinus headache’ and headache-related impact......Page 208
32 Reducing the personal burden of migraine: a patient’s perspective......Page 213
33 The burden of migraine in a sample of doctors of an Italian general hospital in Rome......Page 216
34 The Framig 2000 (II) survey: therapeutical data......Page 221
35 The Framig 2000 (III) survey: health-care use......Page 224
36 Family burden, comorbidities, and health care utilization: discussion summary......Page 226
Section IV Economics of headache......Page 228
37 General principles of disease-costing......Page 230
38 The economic burden of headache......Page 237
39 Measuring the economic benefits of pharmacotherapy—general principles......Page 242
40 The economic cost and benefit of pharmacotherapy for headache......Page 251
41 A stratified approach to migraine management including zolmitriptan is clinically and economically superior to step care approaches: results from the Disability in Strategies of Care (DISC) study......Page 263
42 A comparative study of the effectiveness of eletriptan, Cafergot®, and sumatriptan in reducing the time loss associated with migraine attacks......Page 269
43 The socio-economic impact of migraine in Spain......Page 274
44 Reductions in medical and pharmacy resource utilization associated with the addition of preventive medication to the migraine management strategy......Page 279
45 Utilization and price differentials of selective 5-HT[sub(1)]-receptor agonists in the European countries......Page 283
46 Regaining time lost during migraine attacks with eletriptan......Page 290
47 Economics of headache: discussion summary......Page 295
Section V Guidelines and interventions......Page 298
48 Evidence-based guidelines for migraine headache......Page 300
49 Model interventions to improve headache outcomes in health-care systems......Page 309
50 Model interventions to improve headache outcomes in the workplace......Page 321
51 Analysis of headache patients’ behaviour in the pharmacy: results of a French multicentre study......Page 332
52 Comparison of the efficacy of self-medication and medical prescriptions in reducing the burden of headache......Page 337
53 Evaluation of migraine in the workplace......Page 343
54 Headache patient management in 21 Italian headache centres......Page 347
55 Migraine and chronic idiopathic headache in the French workforce: detection and management. The NOEMIE study protocol......Page 352
56 HIT-6™ scores discriminate among headache sufferers differing in headache-associated workplace productivity loss......Page 357
57 Guidelines and interventions: discussion summary......Page 362
Section VI Improving health-care systems for headache......Page 364
58 Integrating headache services across the primary/secondary-care interface......Page 366
59 Comprehensive academic headache centres......Page 380
60 Headache clinic or pain centre: together or separate......Page 389
61 The first year of the Lariboisière emergency headache centre: a series of 10 510 patients......Page 392
62 Headache symptoms and other headache features in non-specified headaches in primary care......Page 395
63 Headache treatment outcome: a proposed paradigm for quantitative analysis......Page 398
64 Development of HIT-6™, a paper-based short form for measuring headache impact......Page 405
65 Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22 718 adults in Norway......Page 410
66 Reducing the burden of headache by communicating treatment strategies for employees......Page 414
67 The usefulness of the publication, Patient-centered strategies for effective management of migraine, in primary care......Page 421
68 Improving health-care systems for headache: discussion summary......Page 427
A......Page 430
C......Page 431
D......Page 432
F......Page 434
G......Page 435
I......Page 436
K......Page 437
M......Page 438
P......Page 439
S......Page 441
U......Page 443
Z......Page 444